Skip to content
Menu

City Therapeutics, Inc. CTY

Full chart Compare
Set alert

Price alert · CTY

All alert types
19.32 USD +0.97 (+5.29%)

Regular-session close

19.32 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

16.96 Day range 20.62
15.81 52-week range 23.88
YTD
-13.75%
1 year
-13.75%

5D +2.20 (+12.29%)

161820MonTueWedThuFri20.10
Market cap
1.03B
Revenue (ttm)
14.34M
EPS (ttm)
-2.53
Shares out
53.39M
Forward P/E
-6.36
YTD return
-13.75%
1-year return
-13.75%
50-day average
19.45
Volume
250.12K
Avg volume
332.02K
Open
18.35
Previous close
18.35
Day's range
16.96 – 20.62
52-week range
15.81 – 23.88
Analysts
Strong Buy
Price target
37.33 (+93.2%)

Key statistics

200-day average
19.45
Enterprise value
240.52M
Price / sales
71.73
Revenue growth
14.00%
Total cash
169.60M
Total debt
57.04M

Fundamental scorecard

4 of 25 checks passed on CTY’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2026.

Financials — quick view

All financials
CTY Revenue — annual 13.56M
CTY Net income — annual -58.51M
CTY EPS — annual -12.46

Upgrades / downgrades

CTY analyst upgrades and downgrades
DateFirmActionFromTo
Nov 10, 2026Jefferiesinit—Buy
Nov 10, 2026Oppenheimerinit—Outperform
Nov 10, 2026Goldman Sachsinit—Early-Stage Biotech
Nov 10, 2026Stifelinit—Buy

About City Therapeutics, Inc.

City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as retinal diseases and geographic atrophy. It designs and engineers RNAi trigger molecules, such as smaller size, novel cleavage mechanisms, and tailored targeting ligands to enhance potency, specificity, and delivery to various tissue types. Its products includes CITY-FXI, is a city-engineered n-acetylgalactosamine -conjugated small interfering RNA therapeutic targeting factor XI; CITY-RBP4, is a city-engineered GalNAc-conjugated siRNA therapeutic, in development for the treatment of Stargardt disease; CITY-TFR2, is a city-engineered GalNAc-conjugated siRNA therapeutic candidate in development for anemia of chronic disease; The company advances these therapeutics from research through clinical and commercial development stages and engages in strategic collaborations to co-develop RNAi clinical candidates. It has a strategic collaborations with Bausch + Lomb Ireland Limited and Biogen MA Inc. to advance extrahepatic RNAi therapeutics for diseases of the eye and the central nervous system. The company serves clients in the pharmaceutical, biotechnology, and life sciences industries and collaborates with organizations in the ophthalmology sector. The company was incorporated in 2023 and is based in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
citytx.com

News

Your note

Sign in to keep a note on CTY — it syncs with the Stock Master app.

Insider holders

CTY insider holders
InsiderRelationLatest transactionDateShares held
ARCH VENTURE PARTNERS XII, LLCBeneficial Owner of more than 10% of a Class of SecurityPurchaseOct 18, 20260
MARAGANORE JOHN MDirectorConversion of Exercise of derivative securityOct 18, 20262,107,710